Patient empowerment: Rofecoxib revisited

Journal of Rheumatology

Volumn 33, Issue 6, 2006, Pages 1033-1035

  Tannenbaum, Hyman ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; ROFECOXIB;

BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIGESTIVE SYSTEM ULCER; DISEASE SEVERITY; DOCTOR PATIENT RELATION; DRUG EFFECT; DRUG INFORMATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG USE; EDITORIAL; EMPOWERMENT; EVIDENCE BASED MEDICINE; HEART INFARCTION; HIP OSTEOARTHRITIS; HORMONE SUBSTITUTION; HUMAN; INFORMATION DISSEMINATION; ISCHEMIC HEART DISEASE; KNEE OSTEOARTHRITIS; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; RISK MANAGEMENT; STROKE; TELEPHONE; THROMBOTIC STROKE;

AGED; CYCLOOXYGENASE INHIBITORS; DISCLOSURE; HUMANS; LACTONES; OSTEOARTHRITIS; PATIENT ADVOCACY; PATIENT PARTICIPATION; PATIENT SATISFACTION; PHYSICIAN-PATIENT RELATIONS; SULFONES;

EID: 33744778743     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (17)

1. Hawker J, Katz G, Solomon DJ. The patient's perspective on the recall of Vioxx. J Rheumatol 2006;33:1082-8.
2. Tannenbaum H, Bombardier C, Davis P, Russell AS. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference. J Rheumatol 2006;33:140-57.
3. Jenkins JK, Seligman PJ. Analysis and recommendations for agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. [Internet. Cited March 27, 2006]. Available from: http://www.fda.gov/cder/drug/ infopage/COX2/NSAIDdecisionMemo.pdf
4. Health Canada. Report of the Expert Advisory Panel on the Safety of COX-2 Selective Non-steroidal Anti-inflammatory Drugs (NSAIDs). [Internet. Cited April 1, 2006]. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/ activit/sci-consult/cox2/sap_report_gcs_rapport_cox2_e.html
5. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
6. Simon LS. Hyperbole, innuendo, and fact: the strange case of COX-2 selective inhibitors [editorial]. J Rheumatol 2006;33:1-3.
7. Curfman GD, Morrissey S, Drazen JM. Expression of concern: Bombardier, et al. "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8.
8. N Engl J Med 2005;353:2813-4.
9. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
10. Bombardier C, Laine L, Burgos-Vargas R, et al. Response to expression of concern regarding VIGOR study [letter]. N Engl J Med 2006;354:1196-9.
11. Reicin A, Shapiro D. Response to expression of concern regarding VIGOR study [letter]. N Engl J Med 2006;354:1196-9.
12. Targum SL. Memorandum on the cardiovascular safety of rofecoxib. [Internet. Cited April 2, 2006]. Available from: http://www.fda.gov/ohrms/ dockets/ac/01/briefing/3677b2_06_ cardio.pdf
13. US Food and Drug Administration. Sequence of events with VIOXX, since opening of IND. [Internet. Cited April 2, 2006] Available from URL: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4090B1_04_E-FDA-TAB-C.htm
14. Kim PS. An open letter from Merck. December 15, 2005. [Internet. Cited April 2, 2006] Available from URL: http://a248.e.akamai.net/7/248/430/ 20060320212756/www.merck. com/newsroom/vioxx_withdrawal/Merck_Letter.swf
15. Curfman GD, Morrissey S, Drazen JM. Expression of concern reaffirmed [editorial]. N Engl J Med 2006;354:1193.
16. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-1102.
17. Chan AT, Manson JE, Albert CM, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006;113:1578-87.